Sutro Biopharma to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 25-Feb 8:30 AM ET)
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
Globe Newswire (Mon, 23-Feb 8:30 AM ET)
Market Chameleon (Tue, 10-Feb 4:41 AM ET)
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
Globe Newswire (Tue, 10-Feb 7:00 AM ET)
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Wed, 7-Jan 4:05 PM ET)
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globe Newswire (Wed, 17-Dec 4:05 PM ET)
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 16-Dec 4:05 PM ET)
Sutro Biopharma Advances STRO-004 with First Patients Dosed in Pioneering Phase 1 Study
Market Chameleon (Thu, 4-Dec 5:03 AM ET)
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sutro Biopharma trades on the NASDAQ stock market under the symbol STRO.
As of March 6, 2026, STRO stock price climbed to $25.29 with 263,020 million shares trading.
STRO has a beta of 3.86, meaning it tends to be more sensitive to market movements. STRO has a correlation of 0.32 to the broad based SPY ETF.
STRO has a market cap of $414.45 million. This is considered a Small Cap stock.
Last quarter Sutro Biopharma reported $10 million in Revenue and -$6.70 earnings per share. This beat revenue expectation by $887,492 and missed earnings estimates by -$3.00.
In the last 3 years, STRO traded as high as $61.30 and as low as $5.23.
The top ETF exchange traded funds that STRO belongs to (by Net Assets): VTI, VXF, IWC, PRFZ, BIB.
STRO has outperformed the market in the last year with a price return of +86.0% while the SPY ETF gained +16.6%. STRO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +192.0% and +29.3%, respectively, while the SPY returned -1.7% and -1.8%, respectively.
STRO support price is $20.77 and resistance is $24.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STRO shares will trade within this expected range on the day.